Compare Incyte Corporation (INCY) vs Uranium Energy Corp (UEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Uranium Energy Corp — how do they compare? Incyte Corporation trades at $112.77 (market cap $22.85B), while Uranium Energy Corp trades at $9.2 (market cap $4.53B). The key difference: Incyte Corporation is far larger — about 5× Uranium Energy Corp's market cap, and Incyte Corporation is trading nearer its 52-week high, Uranium Energy Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Uranium Energy Corp for 37 Days on average.
| INCY | UEC | |
|---|---|---|
Market Cap | $22.85B | $4.53B |
Volume | 1,927,029 | 10,888,578 |
Sector | Health | Energy |
52-Week High | $129.93 | $20.14 |
52-Week Low | $83.80 | $9.04 |
Typical Hold Time | 33 Days | 37 Days |
Enterprise Value | $18.35B | $4.03B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $113.61, up 0.15% on the day, with a mixed technical signal leaning bearish. The company reported strong 2025 results with revenue of $5.14B and net income of $1.29B, and recent earnings beats in Q1 and Q2 2026. Key developments include FDA approval for Atebrioz and a strategic focus on post-JAKAFI growth targeting $4B in non-JAKAFI sales by 2029.
The outlook is cautiously optimistic, supported by robust profitability and pipeline progress, but tempered by near-term earnings pressure and technical weakness. Risks include JAKAFI's patent expiration after 2029 and competitive threats. Analysts maintain a Buy consensus with a $132.43 price target, implying significant upside from current levels.
UEC trades at $9.27, down 2.11% on the day, amid a bearish technical outlook with 18 sell signals versus 2 buy signals. The company reported a net loss of $87.66 million in 2025, with revenue of $66.84 million, and a negative net income margin of -368.62%. Recent news highlights operational expansion with two in-situ recovery mines ramping up production, supported by strong institutional analyst sentiment with 7 buy ratings and a consensus price target of $16.06.
The investment case balances Wall Street optimism against weak profitability and cash burn. Upside is driven by exposure to growing U.S. uranium demand and multi-mine expansion, but high execution risk, sustained losses, and negative operating cash flow pose significant threats to shareholder value. The stock's trajectory hinges on translating production growth into sustainable profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Uranium Energy Corp
Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.
Read more on UEC →
